Clinical Trials Browser

Phase 2 × Monoclonal Gammopathy of Undetermined Significance × Rituximab × Clear all

NCT00588822 2014-05-06

Rituximab in Treating Patients With Peripheral Neuropathy Caused by Monoclonal Gammopathy of Undetermined Significance

Phase 2 Terminated

21 enrolled 11 charts

Monoclonal Gammopathy of Undetermined Significance, Precancerous Conditions